Answers are grounded in this paper and cite their sources.
It has been proposed that ZNF217, which is amplified at 20q13 in various tumors, plays a key role during neoplastic transformation. ZNF217 has been purified in complexes that contain repressor proteins such as CtBP2, suggesting that it acts as a transcriptional repressor. However, the function of ZNF217 has not been well characterized due to a lack of known target genes. Using a global chromatin immunoprecipitation (ChIP)-chip approach, we identified thousands of ZNF217 binding sites in three tumor cell lines (MCF7, SW480, and Ntera2). Further analysis of ZNF217 in Ntera2 cells showed that many promoters are bound by ZNF217 and CtBP2 and that a subset of these promoters are activated upon removal of ZNF217. Thus, our in vivo studies corroborate the in vitro biochemical analyses of ZNF217-containing complexes and support the hypothesis that ZNF217 functions as a transcriptional repressor. Gene ontology analysis showed that ZNF217 targets in Ntera2 cells are involved in organ development, suggesting that one function of ZNF217 may be to repress differentiation. Accordingly we show that differentiation of Ntera2 cells with retinoic acid led to down-regulation of ZNF217. Our identification of thousands of ZNF217 target genes will enable further studies of the consequences of aberrant expression of ZNF217 during neoplastic transformation. It has been proposed that ZNF217, which is amplified at 20q13 in various tumors, plays a key role during neoplastic transformation. ZNF217 has been purified in complexes that contain repressor proteins such as CtBP2, suggesting that it acts as a transcriptional repressor. However, the function of ZNF217 has not been well characterized due to a lack of known target genes. Using a global chromatin immunoprecipitation (ChIP)-chip approach, we identified thousands of ZNF217 binding sites in three tumor cell lines (MCF7, SW480, and Ntera2). Further analysis of ZNF217 in Ntera2 cells showed that many promoters are bound by ZNF217 and CtBP2 and that a subset of these promoters are activated upon removal of ZNF217. Thus, our in vivo studies corroborate the in vitro biochemical analyses of ZNF217-containing complexes and support the hypothesis that ZNF217 functions as a transcriptional repressor. Gene ontology analysis showed that ZNF217 targets in Ntera2 cells are involved in organ development, suggesting that one function of ZNF217 may be to repress differentiation. Accordingly we show that differentiation of Ntera2 cells with retinoic acid led to down-regulation of ZNF217. Our identification of thousands of ZNF217 target genes will enable further studies of the consequences of aberrant expression of ZNF217 during neoplastic transformation. Amplification at 20q13 occurs in a variety of tumor types, such as breast (1Collins C. Rommens J.M. Kowbel D. Godfrey T. Tanner M. Hwang S.I. Polikoff D. Nonet G. Cochran J. Myambo K. Jay K.E. Froula J. Cloutier T. Kuo W.L. Yaswen P. Dairkee S. Giovanola J. Hutchinson G.B. Isola J. Kallioniemi O.P. Palazzolo M. Martin C. Ericsson C. Pinkel D. Albertson D. Li W.B. Gray J.W. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 8703-8708Crossref PubMed Scopus (273) Google Scholar), gastric (2Yang S.H. Seo M.Y. Jeong H.J. Jeung H.C. Shin J. Kim S.C. Noh S.H. Chung H.C. Rha S.Y. Clin. Cancer Res. 2005; 11: 612-620PubMed Google Scholar), ovarian (3Iwabuchi H. Sakamoto M. Sakunaga H. Ma Y.Y. Carcangiu M.L. Pinkel D. Yang-Feng T.L. Gray J.W. Cancer Res. 1995; 55: 6172-6180PubMed Google Scholar), lung (4Zhu H. Lam D.C. Han K.C. Tin V.P. Suen W.S. Wang E. Lam W.K. Cai W.W. Chung L.P. Wong M.P. Cancer Lett. 2007; 245: 303-314Crossref PubMed Scopus (68) Google Scholar), prostate (5Bar-Shira A. Pinthus J.H. Rozovsky U. Goldstein M. Sellers W.R. Yaron Y. Eshhar Z. Orr-Urtreger A. Cancer Res. 2002; 62: 6803-6807PubMed Google Scholar), and colon (6Lassmann S. Weis R. Makowiec F. Roth J. Danciu M. Hopt U. Werner M. J. Mol. Med. 2007; (in press)PubMed Google Scholar), and is associated with aggressive tumor behavior (7Tanner M.M. Tirkkonen M. Kallioniemi A. Holli K. Collins C. Kowbel D. Gray J.W. Kallioniemi O.P. Isola J. Clin. Cancer Res. 1995; 1: 1455-1461PubMed Google Scholar). The mapping of the amplified region at 20q13.2 led to the positional cloning and characterization of ZNF217 (1Collins C. Rommens J.M. Kowbel D. Godfrey T. Tanner M. Hwang S.I. Polikoff D. Nonet G. Cochran J. Myambo K. Jay K.E. Froula J. Cloutier T. Kuo W.L. Yaswen P. Dairkee S. Giovanola J. Hutchinson G.B. Isola J. Kallioniemi O.P. Palazzolo M. Martin C. Ericsson C. Pinkel D. Albertson D. Li W.B. Gray J.W. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 8703-8708Crossref PubMed Scopus (273) Google Scholar), which is considered to be one of the driver genes at 20q13.2, promoting selection during the early stages of tumor development. Initial comparative genomic hybridization studies showed that ZNF217 is amplified and overexpressed in ∼40% of breast cancer cell lines and 18% of primary breast tumors (8Kallioniemi A. Kallioniemi O.P. Piper J. Tanner M. Stokke T. Chen L. Smith H.S. Pinkel D. Gray J.W. Waldman F.M. Proc. Natl. Acad. Sci. U. S. A. 1994; 91: 2156-2160Crossref PubMed Scopus (698) Google Scholar). Further comparative genomic hybridization studies of various tumor specimens report that ZNF217 amplification and overexpression at the 20q13 locus can display tumor type-specific profiles. For example, an analysis of 22 sporadic colorectal carcinomas detected DNA copy number changes for ZNF217 in 45% of the CIN (chromosomal instability)-type but not the MIN (microsatellite instability)-type sporadic colorectal carcinoma colon tumors (6Lassmann S. Weis R. Makowiec F. Roth J. Danciu M. Hopt U. Werner M. J. Mol. Med. 2007; (in press)PubMed Google Scholar). Evidence in support of a causal role for ZNF217 in tumor formation comes from studies using normal human mammary epithelial cells. Nonet et al. (9Nonet G.H. Stampfer M.R. Chin K. Gray J.W. Collins C.C. Yaswen P. Cancer Res. 2001; 61: 1250-1254PubMed Google Scholar) showed that introduction of ZNF217 into early passage human mammary epithelial cells can lead to a rare event of immortalization. It has been proposed that overexpression of ZNF217 may give a selective advantage to tumor cells by interfering with pathways associated with normal regulation of cell growth, cell death, differentiation, or DNA repair. DNA sequence analysis suggests that ZNF217 encodes a transcription factor having eight DNA binding and a at the (1Collins C. Rommens J.M. Kowbel D. Godfrey T. Tanner M. Hwang S.I. Polikoff D. Nonet G. Cochran J. Myambo K. Jay K.E. Froula J. Cloutier T. Kuo W.L. Yaswen P. Dairkee S. Giovanola J. Hutchinson G.B. Isola J. Kallioniemi O.P. Palazzolo M. Martin C. Ericsson C. Pinkel D. Albertson D. Li W.B. Gray J.W. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 8703-8708Crossref PubMed Scopus (273) Google Scholar). studies support a role for ZNF217 in transcriptional For example, ZNF217 has been identified in complexes that contain repressor proteins such as binding chromatin interfering for and positional binding chromatin interfering for and positional and A. Proc. Natl. Acad. Sci. U. S. A. 2001; PubMed Scopus Google C. R. 2005; PubMed Scopus Google Scholar), the and the C. R. 2005; PubMed Scopus Google Y. W.S. R. J. PubMed Scopus Google C. F. S. T. Y. Mol. 2005; PubMed Scopus Google Y. J. G. F. H. M.P. Y. Y. PubMed Scopus Google Scholar). The of ZNF217 with M. A. P. Yaswen P. D. M. M. Mol. PubMed Scopus Google Scholar) suggests that ZNF217 be to a variety of transcription complexes the of with proteins G. Mol. 2002; PubMed Scopus Google Scholar). biochemical and studies ZNF217 to transcriptional a analysis of role in transcription has been due to a lack of known ZNF217 target genes. we a to thousands of ZNF217 target genes in three cancer cell the breast cancer the colon cancer SW480, and a that can into the role of ZNF217 in transcriptional we the expression of ZNF217 target genes in Ntera2 cells and of the of ZNF217 using and of ZNF217 with using Gene ontology analysis that ZNF217 target genes in Ntera2 cells are transcription that are involved in cell differentiation and organ development. show that ZNF217 upon of Ntera2 cells with retinoic suggesting that the expression of ZNF217 in cells may differentiation, to cells in with and and Ntera2 cells in with and cells at in a For ZNF217 ZNF217 number or number as a into Ntera2 cells using to the cells at for and For ZNF217 Ntera2 cells with the in and at and or and using a number Ntera2 cells using retinoic acid G. S. Kowbel D. H. S. G.B. D. Yaswen P. Collins C. Mol. 2005; PubMed Scopus Google Scholar) and number and as T. Mol. 2001; PubMed Scopus Google Scholar) with can be in et al. J. P. Scholar). in a ZNF217 that using a sequence G. S. Kowbel D. H. S. G.B. D. Yaswen P. Collins C. Mol. 2005; PubMed Scopus Google Scholar). purified a with the number and CtBP2 number from The number from using of the DNA by and by using of a using a Amplification our H. K. R. PubMed Scopus Google Scholar) for and by The human is a of region that and of the transcription are into a of The in from to are at a using with a target of The the the of the of the human and the to by by to the of to ZNF217 binding sites identified the using to amplification of the for of using a and using the to that for the The Amplification from to amplified for hybridization with the The expression for of a from and from to the at as by the and using using the that the of of expression such that the of the expression for the using an by to the of with using the G. J. H.C. PubMed Google The for analyses in ontology function in the and in the the genes and genes with known function from the the that of the number of genes transcriptional regulation and transcription factor and identification of the ZNF217 binding sites the we the in et al. M. M. R. Res. PubMed Scopus Google Scholar) and the of for further these binding sites are identified as that a of in the of the that identified in at of three considered to be binding The human of a of a of human to the in the as and promoters of genomic sequence with a that in a binding be the of a of in for an of binding that the the of the will we that the be well we a to the of a we these in and C. L. G. and P. J. in of promoters by and we considered analysis of these promoters to be and these promoters as a Further of will be C. L. G. and P. J. in of ZNF217 in the ZNF217 is to contain eight and is to be a role in transcriptional regulation has not been well characterized due to a lack of known target genes. Using the approach, studies identified target genes of transcription in a global and F. J. J. E. T.L. PubMed Scopus Google 2002; PubMed Scopus Google Scholar). for are that contain D. J. C. M. P. R. Res. 2005; PubMed Scopus Google Scholar), or of R. 2005; PubMed Scopus Google Scholar). However, we not ZNF217 to or to transcription to our studies we to an analysis of ZNF217 For these we that of the human and genes and for Using a to ZNF217, we in three human cancer cell the breast cancer the colon cancer and the cell Our of a as a binding that the region be bound in at of three M. M. R. Res. PubMed Scopus Google Scholar). three from of the three cell lines to the ZNF217 hybridization by the to a for the that bound by ZNF217 identified with the M. M. R. Res. PubMed Scopus Google Scholar) at the that at in a be in the of the identified a of ZNF217 binding sites in binding sites in and binding sites in Ntera2 cells. the of the binding sites to the we the J. F. A. A. Chen J. J. R. D. C. C. T. R. Google Scholar). analysis identified genes in genes in and genes in Ntera2 cells. that a of the binding sites in SW480, in and in or of the transcription of the binding in the from the as well as genes and in of the binding sites to one region the of that bound by ZNF217 in Ntera2 cells these are the to genomic binding sites of ZNF217 using we it to the of the ZNF217 we Ntera2 cells with to ZNF217 for a the to which ZNF217 can be by the and using the ZNF217 in the the cells. from these to in ZNF217 binding the in the cells with to ZNF217. Thus, of ZNF217 the in the we are that we are ZNF217 target is by retinoic acid in Ntera2 cells. of retinoic acid in Ntera2 down-regulation of ZNF217 by of to the as down-regulation Ntera2 cells are of the of in of a ZNF217 that we identified the of in vivo ZNF217 binding It is not known ZNF217 is bound to the DNA at of these sites or it is to the sites with such as has been to to an in the identification of in the of binding for we a H. S. R. Res. 2007; (in Scholar). the a to the detected from a of using such as G. P. G. G. Res. PubMed Scopus Google Scholar) and for T.L. M. J. PubMed Scopus Google Scholar). a we the ZNF217 binding sites identified using the from three cell a of ZNF217 binding region identified as a binding in at of three in three of the cell of from the of in that not to ZNF217 as a the to these we identified the in is as is with a as is The for positional from the as for and for with a of by our Using these of of the ZNF217 binding of the in the the a to the ZNF217 binding sites of three cell we to we the or we the three cell lines identified in cells with a of for the of for and for and a binding identified in cells with a of for the of for and for The sequence is the identified using the may be due to the that the of the binding sites identified in in the binding sites in the from three cell we to using the Ntera2 binding an identified by the but to the using a It is that the not identified using the Ntera2 the targets a of the number of ZNF217 binding sites in Ntera2 cells. in vitro to a sequence bound by and of ZNF217 M. J. 2007; (in press)PubMed Google Scholar). we not the in of the in vivo ZNF217 binding the sequence of is a in of the of the and of the sites identified by of ZNF217 Using that of the ZNF217 binding sites identified using or of the transcription we that the be for the identification of a of ZNF217 target genes. Using the region to of the transcription sites of human promoters can be with by using the ZNF217 and of Ntera2 cells the ZNF217 hybridization by the to a for the binding sites these we a analysis that of the promoters the for to for the analysis of in The from the ZNF217 for the promoters promoters are and to the of the The in a the Ntera2 for the with a from a that the promoters we identified using the ZNF217 and the are in ZNF217 we ZNF217 and of cells with to ZNF217. identified promoters that showed an of in the cells that the in are the of ZNF217 by a of the for the ZNF217 targets to the of ZNF217 binding at promoters that the targets identified the are bound by ZNF217. The ZNF217 for and of cells with the to ZNF217, can be in the and the in using cells with or to ZNF217, the promoters by ZNF217 in the and the of the promoters into the the for for ZNF217 in the cells and in cells with to are ZNF217 using cells with or to ZNF217, the promoters by ZNF217 in the and the of the promoters into the the for for ZNF217 in the cells and in cells with to are in a ZNF217 binding cell we our to the cancer cell lines and a analysis the and Ntera2 for the for SW480, and Ntera2 Using we the to three of ZNF217 target promoters bound in promoters bound in Ntera2 and promoters bound in and Ntera2 cells. For example, the ZNF217 targets to in cells and in Ntera2 cells. Using the in the to we identified promoters that bound in cells types, ZNF217 targets that and ZNF217 targets that bound in Ntera2 cells for of the three of ZNF217 target targets identified in the targets showed a of with the promoters It that of the promoters that into the cell type-specific in one been as bound in cell or one not show binding in the of cell type-specific ZNF217 targets we using of Ntera2 and cells. chromatin from ZNF217 and chromatin by to that the using to promoters in the of ZNF217 in of the of promoters showed ZNF217 in Ntera2 cells. However, of the promoters not as ZNF217 to the function of ZNF217, we the three of ZNF217 targets using the analysis G. J. H.C. PubMed Google Scholar). analysis ontology to a of genes and a of for the identified by a that the that the identified is in the target be by the the may we a for genes involved in organ and The analysis for the of ZNF217 targets bound in and Ntera2 cells showed for genes with transcription factor and The for transcription factor and organ and for cell differentiation and that a of the ZNF217 target genes transcription such as and The binding of ZNF217 in Ntera2 which are from cell tumors, to the promoters of genes such as proteins suggests that ZNF217 may a role in development. of the genes in the three can be in ontology of ZNF217 target and Ntera2 factor acid factor acid regulation of in a ZNF217 and at studies that ZNF217 can be in a with and CtBP2 with such as and C. F. S. T. Y. Mol. 2005; PubMed Scopus Google Y. J. G. F. H. M.P. Y. Y. PubMed Scopus Google Scholar). ZNF217 is to be a it has been proposed that ZNF217 functions in by and an associated repressor to DNA M. A. P. Yaswen P. D. M. M. Mol. PubMed Scopus Google M. J. 2007; (in press)PubMed Google Scholar). we ZNF217 and proteins are bound to the target in Ntera2 cells using to and the of promoters bound by these proteins we that the of the ZNF217 targets in Ntera2 cells bound by and CtBP2 and the of ZNF217 targets in cells bound by of ZNF217 and target in a It is that ZNF217 to promoters or of and to the the that been characterized M. A. P. Yaswen P. D. M. M. Mol. PubMed Scopus Google Scholar). DNA binding may be the primary the promoters and the repressor For example, studies that proteins can with proteins such as the proteins and T. H. H. Y. Mol. PubMed Google D.C. Proc. Natl. Acad. Sci. U. S. A. PubMed Scopus Google J. M. J. 1998; PubMed Scopus Google Scholar), with the P. C. J. PubMed Scopus Google Scholar), and with DNA binding G. Mol. 2002; PubMed Scopus Google J. M. 2001; PubMed Scopus Google 11: PubMed Scopus Google Scholar). It is that ZNF217 and CtBP2 are to the promoters but to However, the of binding in the genomic binding of ZNF217 and CtBP2 to the in the region not support to the and of ZNF217 and the proteins to promoters by using an to CtBP2 in cells with for ZNF217. in binding of CtBP2 not by removal of ZNF217 from the of bound promoters are in eight of the CtBP2 targets of and of the targets of showed a in binding of CtBP2 in the cells with to ZNF217 of the genes and the CtBP2 and of ZNF217 are in Thus, the ZNF217 and CtBP2 is not for of CtBP2 to Our studies are that the in may be for many ZNF217 as a ZNF217 purified in repressor and we showed that ZNF217 and the many of the suggests that ZNF217 can repress target genes. support for the hypothesis that ZNF217 is a transcriptional we the expression of the target genes. For we ZNF217 using Ntera2 cells and a of promoters that in the targets in of the and a of promoters that in the targets in of the a of promoters genes from and genes from the expression for of ZNF217 target genes using expression from of Ntera2 cells and expression the expression from these and for the analysis of ZNF217 target genes. the ZNF217 the the genes into three having expression having expression and genes that of the Ntera2 targets with a of to a the hypothesis that binding of ZNF217 to a region can in transcriptional ontology analysis of the expression ZNF217 targets showed a for transcription factor organ development, cell differentiation, and development. the of ZNF217 target genes in the in the that of genes may be for ZNF217 we analysis of and using an from Ntera2 for ZNF217 targets and are the ZNF217 targets that in the expression to be bound by ZNF217, one of the ZNF217 targets in the expression to be bound by ZNF217. the of expression may in a of ZNF217 target targets are at genes of in a ontology of ZNF217 targets at factor acid of in a The expression of the of the promoters that binding of ZNF217 can in transcriptional further support for we expression and of ZNF217 by from the and and the to expression ZNF217 to be in three the of the and the of the expression of the three genes or of ZNF217 For example, genes that are by in at of the three with genes by of ZNF217 in three genes by of ZNF217 with down-regulation in three we the of promoters bound by ZNF217 and the of genes that showed a in expression in at of the three we a of the genes having a known function are in of genes to of to of identified as having expression in the cells with to ZNF217 and a in expression of identified as having expression in the and a in expression of ZNF217. The of the promoters and the are identified as ZNF217 targets by the of ZNF217, and the of the promoters and the are identified as ZNF217 targets by the of ZNF217. for a of the of of of by of by of targets by of targets by of identified as having expression in the cells with to ZNF217 and a in expression of identified as having expression in the and a in expression of ZNF217. The of the promoters and the are identified as ZNF217 targets by the of ZNF217, and the of the promoters and the are identified as ZNF217 targets by the of ZNF217. for a of the of in a bound by and by by by in a The genes identified as by are for genes Ntera2 cells of cells and can into and a variety of cell upon with retinoic acid PubMed Scopus Google Scholar), suggesting that one role of ZNF217 may be to in differentiation one that ZNF217 be upon retinoic differentiation of Ntera2 cells. we Ntera2 cells with retinoic acid and at and a for differentiation, we of which is known to be upon differentiation of Ntera2 cells P. D. A. M. J. 2005; PubMed Scopus Google Scholar). that we ZNF217 the we Ntera2 cells (in the of retinoic with for ZNF217. in ZNF217 by of retinoic acid to the as by with The in ZNF217 differentiation of Ntera2 cells the cell the hypothesis that ZNF217 may be in genes. studies will be overexpression of ZNF217 can differentiation in Ntera2 cells. Using the global and of that human we into the function of the ZNF217. by that of the in vivo binding sites of ZNF217 are and identified thousands of promoters bound by ZNF217 in three cancer cell that ZNF217 can function as a transcriptional repressor by that the of ZNF217 target genes are bound by that genes bound by ZNF217 show expression and that in the of ZNF217 bound to a in in we that many of the genes bound by ZNF217 in Ntera2 cells function in the cell suggesting that one role of ZNF217 may be to repress differentiation expression of ZNF217 has been to to amplification at the 20q13 locus in tumor the by which ZNF217 or neoplastic not been It has been proposed that ZNF217 functions as a transcriptional repressor due to in complexes that contain such as CtBP2 and A. Proc. Natl. Acad. Sci. U. S. A. 2001; PubMed Scopus Google C. R. 2005; PubMed Scopus Google C. F. S. T. Y. Mol. 2005; PubMed Scopus Google Y. J. G. F. H. M.P. Y. Y. PubMed Scopus Google Scholar) and such as and Y. W.S. R. J. PubMed Scopus Google C. F. S. T. Y. Mol. 2005; PubMed Scopus Google Scholar). However, an of has not been in due to a lack of known ZNF217 target genes. The thousands of ZNF217 target genes that we identified an for of For example, our analyses of of ZNF217 target genes that of are the target promoters but that of the promoters by ZNF217 of in ZNF217 may the H. S. R. R. D. Res. PubMed Scopus Google Scholar). Further studies are in Our studies support the biochemical in that we that is a the promoters bound by ZNF217 and the promoters bound by in Ntera2 and cancer cells. It is that ZNF217 to promoters or of and to the the that been characterized M. A. P. Yaswen P. D. M. M. Mol. PubMed Scopus Google Scholar). DNA binding may be the primary the promoters and the repressor G. Mol. 2002; PubMed Scopus Google J. M. 2001; PubMed Scopus Google 11: PubMed Scopus Google Scholar). Our binding of ZNF217 and CtBP2 and our in binding of CtBP2 not by removal of ZNF217 from a that ZNF217 and CtBP2 be to the chromatin a hypothesis is by a in many of the ZNF217 binding sites that is from the identified using in vitro and and of ZNF217 M. J. 2007; (in press)PubMed Google Scholar). the that we identified not known binding in the or three of the or the that the of the DNA binding of L.P. PubMed Scopus Google Scholar). Thus, it is that an may to the to the studies that can with and an P. C. J. PubMed Scopus Google Scholar). Our that thousands of promoters bound by ZNF217 is with studies of human transcription such as S. S. Collins Scopus Google Scholar), S. S. P. D. A. J. R. Wong J. M. S. S. H. G. K. PubMed Scopus Google Scholar), M. M. R. Res. PubMed Scopus Google Scholar), R. G. P. S. P. M. S. M. Proc. Natl. Acad. Sci. U. S. A. PubMed Scopus Google Scholar), and the Li J. M. 2005; PubMed Scopus Google Scholar). Further characterization of these target promoters that changes in binding of the factor not lead to changes in expression S. S. Collins Scopus Google R. G. P. S. P. M. S. M. Proc. Natl. Acad. Sci. U. S. A. PubMed Scopus Google Scholar). For example, promoters are bound by the transcriptional but of these genes showed a in expression in that for the S. S. Collins Scopus Google Scholar). we that of the genes identified as ZNF217 targets using showed a in expression ZNF217 by of Ntera2 cells. It is that promoters are by many and that of a factor is not to the regulation of a the of transcriptional regulation in the human has been in of promoters that are by or complexes may be that it may be to the expression of a of genes by complexes from the of our studies of ZNF217 to into expression of factor in human can to many of the genes that are bound by ZNF217 proteins that are in differentiation. showed that ZNF217 are upon differentiation of Ntera2 for the expression of genes involved in differentiation and Thus, we that expression of ZNF217 may lead to a down-regulation of genes that a a of the cells and a and studies will be differentiation of cells of ZNF217. and the and at the the of the for and and for with
No takes yet. Share an insight, caveat, or question.
Krig et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: